Loading
A phase 2 trial of Peginterferon alfa-2b and Temozolomide in Melanoma, run by St. Jude Children's Research Hospital, active and no longer recruiting.
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma is a phase 2 interventional study registered as NCT00539591 by St. Jude Children's Research Hospital, with 29 participants planned, started 2008-05-09 and due to reach its primary completion in 2015-06. Interventions recorded: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b. Conditions recorded: Malignant Melanoma.
Linked to the drug Peginterferon alfa-2b because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
29 enrolled.
95% CI 0.79 to 1.00; Figures from the ClinicalTrials.gov results section (first posted 2014-02-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Probability of Event-free Survival (EFS) of Stratum A Participantsprimary | Peginterferon ɑ-2b/Non-pegylated Interferon ɑ-2b | 23 | 0.913 probability | - | - | link |
Shares Peginterferon alfa-2b and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.
Shares Temozolomide and the tag pipeline.